Seres Therapeutics, Inc. (MCRB) Stock Price

MCRBStock

$5.00−76.03%52W

Market Cap$50.22M

P/E7.89x

PEG Ratio—

Div yield—

Beta0.26

MCRB Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-54.62%

Price vs S&P 500 (4W)-5.97%

VGM Score39.75

P/E Ratio (Annual)7.89x

P/CF (Annual)40.23x

Book Value / Share (Quarterly)$3.51

P/TBV (Annual)13.79x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-71.62%

Cash Flow / Share (Quarterly)$-5.22

Price vs S&P 500 (YTD)-80.64%

Net Profit Margin (TTM)-1192.94%

EPS (TTM)$-2.33

10-Day Avg Trading Volume0.06M

EPS Excl Extra (TTM)$-2.33

Revenue Growth (5Y)-52.34%

EPS (Annual)$0.64

ROI (Annual)12.88%

Net Profit Margin (5Y Avg)-29.07%

Cash / Share (Quarterly)$1.59

P/E Basic Excl Extra (TTM)13.63x

P/E Normalized (Annual)7.89x

ROA (Last FY)4.12%

EBITD / Share (TTM)$-2.92

ROE (5Y Avg)-481.38%

Operating Margin (TTM)-1631.17%

Cash Flow / Share (Annual)$0.09

P/B Ratio1.30x

P/B Ratio (Quarterly)2.21x

Net Income / Employee (Annual)$86,300

EV / Revenue (TTM)15.58x

Net Interest Coverage (TTM)-60.98x

ROA (TTM)-17.94%

EPS Growth QoQ (YoY)60.81%

EV / EBITDA (TTM)6.16x

EPS Incl Extra (Annual)$0.64

Current Ratio (Annual)2.56x

Quick Ratio (Quarterly)2.04x

3-Month Avg Trading Volume0.08M

52-Week Price Return-76.03%

EV / Free Cash Flow (Annual)33.92x

P/E Incl Extra (TTM)13.63x

Revenue / Employee (TTM)$28,500

Tangible BV / Share (Quarterly)$-0.12

P/S Ratio (Annual)56.95x

Asset Turnover (Annual)0.01x

52-Week High$29.98

Operating Margin (5Y Avg)-511.36%

EPS Excl Extra (Annual)$0.64

CapEx CAGR (5Y)-15.67%

Tangible BV CAGR (5Y)-29.22%

26-Week Price Return-43.38%

Quick Ratio (Annual)2.40x

13-Week Price Return-42.11%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)2.11x

Enterprise Value$29.34M

Revenue / Share Growth (5Y)-35.44%

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)25.33%

Revenue / Employee (Annual)$12,000

Pretax Margin (Annual)721.93%

Cash / Share (Annual)$4.79

3-Month Return Std Dev71.13%

Net Income / Employee (TTM)$-340,300

ROE (Last FY)12.88%

Net Interest Coverage (Annual)-12.95x

EPS Basic Excl Extra (Annual)$0.64

P/FCF (TTM)1.55x

Receivables Turnover (TTM)30.88x

EV / Free Cash Flow (TTM)36.84x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-2.33

ROI (TTM)-60.32%

P/S Ratio (TTM)23.86x

Pretax Margin (5Y Avg)-29.07%

Revenue / Share (Annual)$0.09

Tangible BV / Share (Annual)$0.09

Forward P/E33.91x

Price vs S&P 500 (52W)-94.34%

P/E Ratio (TTM)13.63x

Year-to-Date Return-68.68%

5-Day Price Return7.37%

EPS Normalized (Annual)$0.64

ROA (5Y Avg)-23.54%

Net Profit Margin (Annual)721.93%

Month-to-Date Return-3.52%

Cash Flow / Share (TTM)$-1.06

EBITD / Share (Annual)$-1.03

Operating Margin (Annual)-1683.90%

LT Debt / Equity (Annual)0.00x

P/CF (TTM)69.50x

ROI (5Y Avg)-95.46%

P/E Excl Extra (TTM)13.63x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-2.33

P/B Ratio (Annual)3.04x

Pretax Margin (TTM)-1192.94%

Book Value / Share (Annual)$4.63

Price vs S&P 500 (13W)-44.91%

Beta0.26x

P/FCF (Annual)51.95x

Revenue / Share (TTM)$0.19

ROE (TTM)-60.32%

52-Week Low$4.32

vGradeC

gGradeD

mGradeD

vgmGradeD

MCRB Earnings Surprise History

Q2 25-2.27est. -2.27

Q3 250.94est. 1.28

Q4 25-1.76est. -1.60

Q1 26-2.08est. -1.88

Q2 261.07est. -2.19

MCRB Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.14

4.13

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
MCRBSeres Therapeutics, Inc.	C	D	D	$5.00
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Seres Therapeutics, Inc.

Seres Therapeutics is a microbiome therapeutics company developing biological drugs designed to restore and repair the function of dysbiotic microbiomes. The company's lead product, SER-109, is designed to prevent recurrent Clostridium difficile infection (CDI), a serious colon infection. The company is also advancing a pipeline of additional candidates including SER-262, SER-287, and SER-401.